Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Chubb
Dow
Chinese Patent Office
Express Scripts
Healthtrust
Cerilliant
Covington

Generated: May 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,479,535

« Back to Dashboard

Summary for Patent: 6,479,535
Title: 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
Abstract:The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: ##STR1##
Inventor(s): Pickar; James Harrison (Springfield, PA), Komm; Barry Samuel (Havertown, PA)
Assignee: Wyeth (Madison, NJ)
Application Number:09/306,073
Patent Claims: 1. A pharmaceutical composition comprising a pharmaceutically effective amount of 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically effective amount of conjugated estrogens.

2. A method of treating vasomotor symptoms in a postmenopausal or estrogen deficient woman in need thereof, which comprises administering to said woman an effective amount of a combination of 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol- 5-ol and conjugated estrogens.

3. The method according to claim 2, wherein the vasomotor symptom is hot flushes.

4. A method of inhibiting or retarding bone demineralization or treating or inhibiting osteoporosis in a postmenopausal or estrogen deficient woman in need thereof, which comprises administering to said woman an effective amount of a combination of 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol and conjugated estrogens.

5. A method of treating or inhibiting menopausal or postmenopausal disorders in a postmenopausal or estrogen deficient woman in need thereof, which comprises administering to said woman an effective amount of a combination of 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol and conjugated estrogens.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Citi
US Army
Healthtrust
Dow
Deloitte
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.